| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f9533575751b2321d1ec25271480dc9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate |
2020-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42621d81b8dd97e2c2de77d5da10c922
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e9405b06a882507d458b247a315c960
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cc8b7b919528c7f99de051ea6b16bed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e446d9988bbd57d62054b5345015019b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3898e994fecb4195502928b583001f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4416a1e74b2990ff2252dfba24b7aef3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a41dfe2f57022d1ded3004129c865dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f70e22bc370102ad4cbcf1df087803c |
| publicationDate |
2022-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022169646-A1 |
| titleOfInvention |
Heterocyclic compounds and uses thereof |
| abstract |
Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology. |
| priorityDate |
2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |